A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.

The registered record

Accession number

NCT07029828

Lead sponsor

Pfizer (industry)

Registered condition naming hair loss

Severe Alopecia Areata

Official title

A LONG-TERM, DOUBLE-BLIND EXTENSION STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF RITLECITINIB IN PARTICIPANTS WITH SEVERE ALOPECIA AREATA WHO PREVIOUSLY COMPLETED STUDIES B7981027 OR B7981031

Interventions

• DrugRitlecitinib higher dose
• DrugRitlecitinib lower dose

Names and types as registered. The sponsors' free-text descriptions of these interventions are not reproduced: they are written by the party with an interest in the result, and reprinting them inside this site's layout would lend them this site's voice.

Design

Study type

interventional

Phase

Phase 3

Allocation

randomized

Masking

quadruple

Primary purpose

treatment

Enrolment

140 participants (estimated)

Sites

41 locations in China, Czechia, France, Japan, Poland, United States

What it measures

1. Incidence of treatment-emergent adverse events (AEs).

   Time frame: From the time participant signs informed consent/assent, through and including a minimum of 28 calendar days after the last administration of the study intervention (up to approximately 3 years).

2. Incidence of Serious Adverse Events (SAEs) and AEs leading to permanent discontinuation from the study.

   Time frame: From the time participant signs informed consent/assent, through and including a minimum of 28 calendar days after the last administration of the study intervention (up to approximately 3 years).

Primary outcome measures only, as registered. What a trial chose to measure, and when, is the most informative thing about it that is knowable before it reports — a hair-count endpoint at 24 weeks and a patient-satisfaction endpoint at 12 weeks are not the same study.

Who can take part

Sex

all

Age

6 Years to 14 Years

Healthy volunteers

not accepted

A summary of three registered fields, not the eligibility criteria. The full inclusion and exclusion criteria, the recruiting sites and the study contacts are on the registry record, which is the only place they are maintained. This site has no relationship with this trial and cannot refer anyone to it.

Registered dates

Study start

10 September 2025 (actual)

Primary completion

26 June 2030 (estimated)

Study completion

26 June 2030 (estimated)

First posted

19 June 2025 (actual)

Last update posted

28 April 2026 (actual)

"Estimated" and "actual" are the registry's own labels: an estimated date is a plan, and plans move. A date is printed at the precision it was registered at: this record registers a primary completion to the day, so a day is what is shown. Where a sponsor registers only a month, only a month is shown.

Results

This trial has not reported results. ClinicalTrials.gov holds no results record for it. That is the ordinary state of a trial that is running or about to run, and it means there is nothing here to tell you about whether the intervention works — including nothing negative. If this page implied otherwise it would be wrong.

On this site

Guides covering the condition this trial is registered for. They are about published evidence; this page is about a registration, and the two do not overlap.

Alopecia Areata: Types, Treatment, and OutlookJAK Inhibitors for Alopecia Areata: Baricitinib, Ritlecitinib and Deuruxolitinib, Trial by Trial

Where this came from

Read from the ClinicalTrials.gov API on 6 September 2026 and rebuilt into this page without alteration. ClinicalTrials.gov is a service of the U.S. National Library of Medicine and is the authority on this record; where this page and the registry disagree, the registry is right. This page is not affiliated with or endorsed by NLM or NIH, or with the sponsor of this trial.

Open NCT07029828 on ClinicalTrials.gov · All 157 trials in the pipeline